28.45
-0.18 (-0.63%)
| Penutupan Terdahulu | 28.63 |
| Buka | 28.51 |
| Jumlah Dagangan | 2,027,184 |
| Purata Dagangan (3B) | 1,960,235 |
| Modal Pasaran | 4,741,190,656 |
| Harga / Pendapatan (P/E TTM) | 19.90 |
| Harga / Pendapatan (P/E Ke hadapan) | 25.58 |
| Harga / Jualan (P/S) | 3.27 |
| Harga / Buku (P/B) | 2.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Margin Keuntungan | 23.30% |
| Margin Operasi (TTM) | 4.50% |
| EPS Cair (TTM) | 2.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -12.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -39.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.90% |
| Nisbah Semasa (MRQ) | 3.33 |
| Aliran Tunai Operasi (OCF TTM) | 516.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 429.53 M |
| Pulangan Atas Aset (ROA TTM) | 11.62% |
| Pulangan Atas Ekuiti (ROE TTM) | 25.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Alkermes plc | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.60 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.49% |
| % Dimiliki oleh Institusi | 107.53% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tig Advisors, Llc | 31 Dec 2025 | 3,859,122 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 45.00 (RBC Capital, 58.17%) | Beli |
| 45.00 (Wolfe Research, 58.17%) | Beli | |
| Median | 44.00 (54.66%) | |
| Rendah | 34.00 (B of A Securities, 19.51%) | Pegang |
| Purata | 41.75 (46.75%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 31.69 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 26 Feb 2026 | 45.00 (58.17%) | Beli | 30.73 |
| Wells Fargo | 26 Feb 2026 | 43.00 (51.14%) | Beli | 30.73 |
| Wolfe Research | 24 Feb 2026 | 45.00 (58.17%) | Beli | 33.39 |
| B of A Securities | 20 Feb 2026 | 34.00 (19.51%) | Pegang | 31.91 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Jan 2026 | Pengumuman | Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 |
| 30 Dec 2025 | Pengumuman | Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |